Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model

Cancer Immunology, Immunotherapy

Volumn 59, Issue 4, 2010, Pages 541-551

  Ginzkey, Christian ^a,b   Eicker, Sven O ^a   Marget, Matthias ^a   Krause, Joerg ^a   Brecht, Stephan ^a   Westphal, Manfred ^c   Hugo, Hans H ^a   Mehdorn, H M ^a   Steinmann, Joerg ^a   Hamel, Wolfgang ^a,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cpg; Glioma; Rat oligonucleotides; Stereotactic

Indexed keywords

CHROMIUM 51; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; PERFORIN; PROTEIN ED1; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CD68 PROTEIN, RAT; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; DIFFERENTIATION ANTIGEN; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BRAIN TISSUE; CANCER IMMUNOTHERAPY; CANCER SIZE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GLIOSARCOMA; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MALE; MICROGLIA; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SPLEEN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR NECROSIS; ANIMAL; BRAIN TUMOR; CELL MOTION; CYTOLOGY; CYTOTOXICITY; DISEASE MODEL; FISCHER 344 RAT; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GLIOSARCOMA; HISTOCOMPATIBILITY ANTIGENS CLASS II; INJECTIONS, INTRALESIONAL; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; OLIGODEOXYRIBONUCLEOTIDES; RATS; RATS, INBRED F344; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 77449095659     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0771-y     Document Type: Article

References (33)

1. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY (2001) Implication of macrophages in tumor rejection induced by CpG- oligodeoxynucleotides without antigen. Clin Cancer Res 7: 3540-3543 (Pubitemid 33069992)
2. Badie B, Bartley B, Schartner J (2002) Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol 133: 39-45 (Pubitemid 35346726)
3. Badie B, Schartner J, Prabakaran S, Paul J, Vorpahl J (2001) Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol 120: 19-24 (Pubitemid 33016720)
4. Barclay AN (1981) The localization of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues. Immunology 42: 593-600
5. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL (2007) Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpGoligodeoxynucleotides. Immunology 120: 412-423
6. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Benin A, Tibi A, Martin-DuverneuiI N, Sanson M, Lacomblez L, Taillibert S, Puybasset L, Van Effenterre R, Delattre JY, Carpentier AF (2006) Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8: 60-66 (Pubitemid 43154452)
7. Carpentier AF, Meng Y (2006) Recent advances in immunotherapy for human glioma. Curr Opin Oncol 18: 631-636 (Pubitemid 44427639)
8. Carpentier AF, Xie J, Mokhtari K, Delattre JY (2000) Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6: 2469-2473 (Pubitemid 30399217)
9. Damoiseaux JG, Dopp EA, Calame W, Chao D, MacPherson GG, Dijkstra CD (1994) Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. Immunology 83: 140-147 (Pubitemid 24285411)
10. Ehtesham M, Black KL, Yu JS (2004) Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11: 192-207 (Pubitemid 38758224)
11. El Andaloussi A, Han Y, Lesniak MS (2006) Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105: 430-437 (Pubitemid 44358755)
12. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS (2006) Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with, experimental brain tumors. Glia 54: 526-535 (Pubitemid 44449333)
13. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66: 3294-3302
14. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH (2006) Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12: 4294-4305
15. Ginzkey C, Eicker SO, Krause J, Brecht S, Hugo HH, Marget M, Mehdorn HM, Steinmann J, Hamel W (2009) DNA vaccination against rat gliomas expressing the E. coli lacZ gene as a model antigen (submitted)
16. Graeber MB, Scheithauer BW, Kreutzberg GW (2002) Microglia in brain tumors. Glia 40: 252-259
17. Grauer OM, Moiling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ (2008) TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 181: 6720-6729
18. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164: 1617-1624 (Pubitemid 30067282)
19. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409-417 (Pubitemid 34141815)
20. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS (2007) Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67: 774-781 (Pubitemid 46709446)
21. Jander S, Schroeter M, D'Urso D, Gillen C, Witte OW, Stall G (1998) Focal ischaemia of the rat brain elicits an unusual inflammatory response: early appearance of CD8+ macrophages/ microglia. Eur J Neurosci 10: 680-688 (Pubitemid 28325490)
22. Jurk M, Vollmer J (2007) Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 21: 387-401 (Pubitemid 350145447)
23. Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117: 1184-1194 (Pubitemid 46718403)
24. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY (2005) Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116: 992-997 (Pubitemid 41209208)
25. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4: 437-447 (Pubitemid 44197039)
26. Perry VH, Gordon S (1987) Modulation of CD4 antigen on macrophages and microglia in rat brain. J Exp Med 166: 1138-1143
27. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E (1997) Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3: 849-854 (Pubitemid 27353443)
28. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H (2007) Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 8: 1002-1008
29. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B (2005) Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51: 279-285 (Pubitemid 41532103)
30. Schluesener HJ, Seid K, Deininger M, Schwab J (2001) Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides. J Neuroimmunol 113: 89-94 (Pubitemid 32008674)
31. Steinmann J, Kaden J, May G, Schroder K, Herwartz C, Muller-Ruchholtz W (1994) Failure of in vitro T-cell assays to predict clinical outcome after human kidney transplantation. J Clin Lab Anal 8: 157-162 (Pubitemid 24145709)
32. Watters JJ, Schartner JM, Badie B (2005) Microglia function in brain tumors. J Neurosa Res 81: 447-455
33. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A (2003) Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivinRNA-transfected dendritic cells. J Immunol 170: 5391-5397 (Pubitemid 36617824)